Supplementary Material for

Tobacco mosaic virus for the targeted delivery of drugs to cells expressing prostate-specific membrane antigen

Sourabh Shukla[1#], Isaac Marks[1#], Derek Church[1], Soo-Khim Chan[1], Jonathan K. Pokorski[1,5,6], Nicole F. Steinmetz[1,2,3,4,5,6]*

[1]Department of NanoEngineering, [2]Bioengineering, [3]Radiology, [4]Moores Cancer Center, [5]Center for Nano-ImmunoEngineering, [6]Institute for Materials Discovery and Design, University of California, San Diego, La Jolla, CA 92093 USA.

#these authors contributed equally

*corresponding author: nsteinmetz@ucsd.edu

Figure S1

A



B



Figure S1. Analysis of compound (**1**) by **(A)** ^{1}H-NMR in $CDCl_3$ and **(B)** ESI-MS. The peak at 5.3 ppm represents residual CH_2Cl_2 and the peaks at 4.12, 2.06 and 1.3 ppm represent residual ethyl acetate. Theoretical mass [M] calculated for $C_{29}H_{53}N_3O_9$ was 587.38; protonated experimental mass found was $[M+H]^+$ 588.42.

Figure S2
A



B



Figure S2. Analysis of compound (**3**) = DUPA-PEG$_4$-DBCO by **(A)** reversed-phase HPLC and **(B)** ESI-MS. Theoretical mass [M] calculated for $C_{42}H_{55}N_5O_{14}$ was 853.37; protonated experimental mass found was $[M+H]^+$ 854.26.